A PROTAC compound of remdesivir or its intermediates, a preparation method thereof, and application thereof in anti-EV71
By developing PROTAC compounds of remdesivir or GS-441524, the ubiquitination pathway targeted degradation of EV71 viral RNA-dependent RNA polymerase, the problem of insufficient treatment of EV71 virus was solved by existing drugs and effective viral inhibition was achieved and drug resistance overcome, demonstrating biological activity comparable to remdesivir.
Patent Information
- Application Number
- CN202211520619.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-11-29
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-11-29
AI Technical Summary
The existing drugs lack effective treatment options for enterovirus type 71 (EV71), which leads to a threat to public health and safety. The vaccine is ineffective due to genomic mutations, and it is urgent to develop new antiviral drugs.
The PROTAC compound based on remdesivir or the intermediate GS-441524 was developed to target the RNA-dependent RNA polymerase of the EV71 virus through the ubiquitination pathway to inhibit viral replication.
Effective inhibition of EV71 virus was achieved, RNA-dependent RNA polymerase was degraded, the effect of antiviral drugs was significantly improved, drug resistance problem was overcome, and biological activity comparable to remdesivir was demonstrated.
Smart Images

Figure CN115819423B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology and relates to a PROTAC compound based on remdesivir or its intermediate GS-441524, a preparation method thereof, and an application thereof in resisting EV71 virus. Background Art
[0002] Enterovirus 71 (EV71) is a member of the genus Enterovirus in the Picornaviridae family. It is a positive-sense single-stranded RNA virus containing an open reading frame encoding four capping proteins (VP1-4) and seven nonstructural proteins (2A, 2B, 2C, 3A, 3B, 3C, and 3D). The 3D (also known as 3Dpci1) protein, as the viral RNA-dependent RNA polymerase (RdRp), plays a major role in the synthesis of the viral negative strand and the uridylation of some proteins. In the past 20 years, EV71 has caused epidemics and sporadic outbreaks of hand, foot and mouth disease (HFMD), and can also induce severe neurological / cardiopulmonary complications such as aseptic meningitis, acute flaccid paralysis, encephalitis, myocarditis, pulmonary edema and hemorrhage, leading to death, making it one of the most pathogenic enteroviruses.
[0003] Enterovirus 71 (EV71) is one of the viruses that still poses a threat to global health, but the FDA has not approved specific drugs for clinical use. In order to deal with the threat of EV71 to public health security, vaccine prevention and symptomatic treatment are the only remaining clinical response measures. However, due to genomic mutations, it is useless and ineffective for infected people, so there is an urgent need to develop new antiviral drugs to treat ER-A71 infection. Summary of the invention
[0004] The primary purpose of the present invention is to overcome the deficiencies of existing drugs and provide a PROTAC compound of remdesivir or its intermediate GS-441524. The PROTAC compound of remdesivir or GS-441524 has anti-EV71 virus activity and can be developed as a new anti-EV71 virus drug with broad application prospects.
[0005] Another object of the present invention is to provide a method for preparing a PROTAC compound of remdesivir or GS-441524.
[0006] In order to achieve the above object, the technical solution adopted by the present invention is as follows:
[0007] In the first aspect, the present invention provides a PROTAC compound of remdesivir or GS-441524. The structure of the PROTAC compound of remdesivir is shown in the general formula (I); the structure of the PROTAC compound of GS-441524 is shown in the general formula (II) or (III).
[0008]
[0009]
[0010] In the above general formula, the E3 ligase ligand is a small molecule protease ligand encoded by the VHL (von Hippel-Lindau), CRBN (Cereblon) or RNF114 gene with ubiquitination function, specifically including
[0011] In addition, E3 ligase ligands can also be hydrophobic tag small molecule ligands, including
[0012] Linker is a connecting group, which represents -alkylene or -alkoxy, wherein the -alkylene or -alkoxy is a straight chain or branched alkylene or alkoxy which is optionally interrupted one or more times by one or more groups selected from the following groups, such as -(CH2) n -、-(CH2) n CO-、-NR1(CH2) n CO-、-NR2(CH2) n -、-(OCH2CH2O) n -、-(CH2CH2O) n -、-(OCH2CH2OCH2) n -、-(CH2CH2OCH2) n -、-(CH2CH2OCH2CH2) n -, heteroaromatic hydrocarbon group or any combination thereof, wherein n represents a natural number from 1 to 20, R1 and R2 are each independently selected from H or C 1-10 alkyl.
[0013] Preferably, the remdesivir or GS-441524 PROTAC compounds provided by the present invention include but are not limited to the compounds shown in Table 1 below:
[0014] Table 1
[0015]
[0016]
[0017]
[0018]
[0019]
[0020]
[0021] In a second aspect, the present invention provides a PROTAC compound of any one of the above-mentioned remdesivir or GS-441524 or a pharmacologically or physiologically acceptable salt thereof as an RNA-dependent RNA polymerase inhibitor degrader in the preparation of an anti-EV71 drug.
[0022] In a third aspect, the present invention provides an anti-EV71 pharmaceutical composition or an RNA-dependent RNA polymerase inhibitor, comprising the above-mentioned PROTAC compound of remdesivir or GS-441524 or a pharmacologically or physiologically acceptable salt thereof, and also comprising a pharmaceutically acceptable carrier or excipient.
[0023] In a fourth aspect, the present invention provides a method for preparing the above-mentioned PROTAC compound of remdesivir or GS-441524, and the PROTAC compound of remdesivir or GS-441524 is divided into series I PROTAC compound of remdesivir, series II PROTAC compound of GS-441524, series III PROTAC compound of GS-441524, series IV PROTAC compound of GS-441524, and series V PROTAC compound of GS-441524.
[0024] Among them, the PROTAC compound of series I remdesivir is a compound represented by the general formula (I), the linker is an alkylene chain or an alkoxy chain with n=6-20, and the E3 ligase is the above-mentioned methylated VHL.
[0025] The PROTAC compound of series II GS-441524 is a compound represented by the general formula (II), the linker is an alkylene chain with n=6-10, and the E3 ligase is the above-mentioned methylated VHL.
[0026] The PROTAC compound of series III GS-441524 is a compound represented by the general formula (III), the linker is an alkylene or alkoxy chain with n=6-20, and the E3 ligase is the above-mentioned methylated VHL or trans-methylated VHL.
[0027] The PROTAC compound of series IV GS-441524 is a compound represented by the general formula (III), the linker is an alkylene chain with n=6-20, and the E3 ligase is the above-mentioned lenalidomide, methyl lenalidomide or benzodione piperidine.
[0028] The PROTAC compound of series V GS-441524 is a compound represented by the general formula (III), the linker is an alkylene chain with n=6-11, and the E3 ligase is the above-mentioned Boc lysine, 9-aminofluorene, and RNF-114 ligand.
[0029] The preparation method of the PROTAC compound of series I remdesivir comprises the following steps:
[0030] A VHL derivative having an alkanoic acid terminal and an alkyl chain or an alkoxy chain as the connecting chain reacts with remdesivir in a solvent under the conditions of HATU (O-(7-azabenzotriazole-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate) and DIPEA (N,N-diisopropylethylamine) to obtain a PROTAC compound of series I remdesivir; the solvent is preferably anhydrous DCM (dichloromethane) or DMF (N,N-dimethylformamide) or a mixed solution of the two, the reaction is preferably carried out at 0-25°C, and the reaction time is preferably 1h-12h.
[0031]
[0032] Series I Synthetic Route of PROTAC Compounds of Remdesivir
[0033] A method for preparing a PROTAC compound of series II GS-441524 comprises the following steps:
[0034] The VHL derivative with an alkanoic acid terminal and an alkyl chain as the connecting chain reacts with GS-441524 in a solvent under HATU and DIPEA conditions to obtain a PROTAC compound of series II GS-441524; the solvent is preferably DCM or DMF or a mixed solvent of the two, the reaction is preferably carried out at 0-25°C, and the reaction time is preferably 1h-12h.
[0035]
[0036] Synthetic route of PROTAC compounds of series II GS-441524
[0037] The preparation method of the PROTAC compound of series III GS-441524 includes the following three methods:
[0038] (1) GS-441524 reacts with 2,2-dimethoxypropane and concentrated sulfuric acid in acetone to obtain a key intermediate protected with 2'-OH, 3'-OH, and the reaction time is preferably 1h-3h. The intermediate and the single alkyl chain VHL derivative removed from the tert-butyl ester are then reacted in a solvent under the conditions of EDCI (1-ethyl-3 (3-dimethylpropylamine) carbodiimide) and DMAP (4-dimethylaminopyridine) to obtain a PROTAC compound of GS-441524 protected with 2'-OH, 3'-OH, and the solvent is preferably DCM or DMF or a mixed solvent of the two. The reaction is preferably carried out at 0-25°C, and the reaction time is preferably 1h-12h. Finally, the protecting group is removed under acidic conditions at 0-25°C to obtain a PROTAC compound of series III GS-441524.
[0039]
[0040] Series III (1) Synthetic route of PROTAC compounds of GS-441524
[0041] (2) The 2'-OH, 3'-OH protected GS-441524 key intermediate and the single alkyl chain VHL derivative removed from the tert-butyl ester are then reacted in a solvent under EDCI and DMAP conditions to obtain a PROTAC compound of 2'-OH, 3'-OH protected GS-441524, wherein the solvent is preferably DCM or DMF or a mixed solvent of the two, and the reaction is preferably carried out at 0-25°C for 1h-12h. Finally, the protecting group is removed under acidic conditions at 0-25°C to obtain a PROTAC compound of series III GS-441524.
[0042]
[0043] Series III (2) Synthetic route of PROTAC compounds of GS-441524
[0044] (3) The methylated VHL derivative with a bromine atom substituted at the end and a single alkyl chain as the connecting chain and the 2'-OH, 3'-OH protected GS-441524 key intermediate are dissolved in a solvent with potassium carbonate and potassium iodide, and the reaction is refluxed at 60-85°C to obtain a PROTAC compound of 2'-OH, 3'-OH protected GS-441524, wherein the solvent is preferably acetonitrile or DMF, and the reaction time is preferably 6-12h. Finally, the protecting group is removed under acidic conditions at 0-25°C to obtain a PROTAC compound of series III GS-441524.
[0045]
[0046] Series III (3) Synthetic route of PROTAC compounds of GS-441524
[0047] The preparation of PROTAC compounds of series IV GS-441524 includes the following two methods:
[0048] (1) A CRBN derivative with an alkanoic acid terminal and an alkoxy chain as a connecting chain reacts with a 2'-OH, 3'-OH protected GS-441524 intermediate in a solvent under EDCI and DMAP conditions to obtain a 2'-OH, 3'-OH protected GS-441524 PROTAC compound, wherein the solvent is preferably DCM, DMF or a mixed solvent of the two, and the reaction is preferably carried out at 0-25°C, and the reaction time is preferably 1h-12h. Finally, the protecting group is removed under acidic conditions at 0-25°C to obtain a series IV GS-441524 PROTAC compound.
[0049]
[0050] Synthetic route of PROTAC compounds of series IV GS-441524
[0051] (2) The benzodione piperidine with an alkanoic acid terminal and an alkoxy chain as the connecting chain reacts with the 2'-OH, 3'-OH protected GS-441524 intermediate in a solvent under EDCI and DMAP conditions to obtain a 2'-OH, 3'-OH protected GS-441524 PROTAC compound, wherein the solvent is preferably DCM, DMF or a mixed solvent of the two, and the reaction is preferably carried out at 0-25°C, and the reaction time is preferably 1h-12h. Finally, the protecting group is removed under acidic conditions at 0-25°C to obtain a series III GS-441524 PROTAC compound.
[0052]
[0053] Synthetic route of PROTAC compounds of series IV GS-441524
[0054] The preparation method of PROTAC compounds of series V GS-441524 includes the following three methods:
[0055] (1) A long-chain alkanoic acid with a Boc (tert-butyloxycarbonyl) protected amino group at the end reacts with a 2'-OH, 3'-OH protected GS-441524 intermediate in a solvent under EDCI and DMAP conditions to obtain a Linker conjugate compound of 2'-OH, 3'-OH protected GS-441524, wherein the solvent is preferably DCM, DMF or a mixed solvent of the two, and the reaction is preferably carried out at 0-25°C, and the reaction time is preferably 1h-12h. Subsequently, the protecting group is removed under acidic conditions at 0-25°C to obtain GS-441524 connected to a long alkyl chain and with a naked amino group at the end, and finally reacts with a Boc protected lysine to obtain a PROTAC compound of series V GS-441524.
[0056]
[0057] Synthetic route of PROTAC compounds of series V GS-441524
[0058] (2) A 9-aminofluorene derivative with an alkanoic acid terminal and an alkoxy chain as a connecting chain reacts with a 2'-OH, 3'-OH protected GS-441524 intermediate in a solvent under EDCI and DMAP conditions to obtain a PROTAC compound of 2'-OH, 3'-OH protected GS-441524, wherein the solvent is preferably DCM, DMF or a mixed solvent of the two, and the reaction is preferably carried out at 0-25°C, and the reaction time is preferably 1h-12h. Finally, the protecting group is removed under acidic conditions at 0-25°C to obtain a PROTAC compound of series V GS-441524.
[0059]
[0060] Synthetic route of PROTAC compounds of series V GS-441524
[0061] (3) The RNF-114 with an alkanoic acid terminal and an alkoxy chain as the connecting chain reacts with the 2'-OH, 3'-OH protected GS-441524 intermediate under EDCI and DMAP conditions in a solvent to obtain a PROTAC compound of 2'-OH, 3'-OH protected GS-441524, wherein the solvent is preferably DCM, DMF or a mixed solvent of the two, and the reaction is preferably carried out at 0-25°C, and the reaction time is preferably 1h-12h. Finally, the protecting group is removed under acidic conditions at 0-25°C to obtain a PROTAC compound of series V GS-441524.
[0062]
[0063] Synthetic route of PROTAC compounds of series V GS-441524
[0064] In the preparation method of the above-mentioned series I PROTAC compound, the molar ratio of remdesivir, VHL derivative, HATU and DIPEA is 1.1:1:1.1:4.0.
[0065] In the preparation method of the above-mentioned series II PROTAC compound, the molar ratio of GS-441524, VHL derivative, HATU and DIPEA is 1.1:1:1.1:4.0.
[0066] In the preparation method (1) (2) (3) of the above series III PROTAC compounds, the molar ratio of GS-441524, 2,2-dimethoxypropane, and concentrated sulfuric acid is 1:2:0.05; the molar ratio of 2'-OH, 3'-OH protected GS-441524 intermediate, VHL derivative, EDCI, and DMAP is 1:1.1:1.1:1.2; and the volume ratio of HCl and THF is 0.2:1.
[0067] In the preparation method (1) of the above series IV PROTAC compounds, the molar ratio of the 2'-OH, 3'-OH protected GS-441524 intermediate, CRBN derivative, EDCI, and DMAP is 1:1.1:1.1:1.2; the volume ratio of HCl and THF is 0.2:1. In the preparation method (2) of the above series IV PROTAC compounds, the molar ratio of the 2'-OH, 3'-OH protected GS-441524 intermediate, benzodione piperidine derivative, EDCI, and 2DMAP is 1:1.1:1.1:1.2; the volume ratio of HCl and THF is 0.2:1.
[0068] In the preparation method (1) of the above series V PROTAC compounds, the molar ratio of the 2'-OH, 3'-OH protected GS-441524 intermediate, the alkyl acid derivative of the terminal Boc amino group, EDCI and DMAP is 1:1.1:1.1:1.2; the volume ratio of HCl and EA is 0.2:1; the molar ratio of the GS-441524 derivative, Boc lysine, HATU and DIPEA is 1.1:1:1.1:4.0. In the preparation method (2) of the above series V PROTAC compounds, the molar ratio of the 2'-OH, 3'-OH protected GS-441524 intermediate, the 9-aminofluorene derivative, EDCI and DMAP is 1:1.1:1.1:1.2; the volume ratio of HCl and THF is 0.2:1. In the preparation method (3) of the above series V PROTAC compounds, the molar ratio of the 2'-OH, 3'-OH protected GS-441524 intermediate, the RNF-114 ligand derivative, EDCI and DMAP is 1:1.1:1.1:1.2; the volume ratio of HCl and THF is 0.2:1.
[0069] The PROTAC compound of remdesivir or GS-441524 involved in the present invention can effectively degrade the RNA polymerase that the EV71 virus RNA depends on, thereby exerting the activity of inhibiting the replication of the EV71 virus, and has low toxicity to cells, and can be used to prepare drugs against the EV714 virus. BRIEF DESCRIPTION OF THE DRAWINGS
[0070] Figure 1 It is a Western Blot diagram of the degradation of EV71 RdRp by some compounds of the present invention. DETAILED DESCRIPTION
[0071] The features and advantages of the present invention can be further understood through the following detailed description. The examples provided are merely illustrative of the methods of the present invention and are not intended to limit the remainder of the present invention in any way.
[0072] [Example 1] Preparation of VHL derivatives with carboxylic acid at the end
[0073] The VHL derivative with an alkyl chain substituted with carboxylic acid at the end is synthesized by the reactions shown in the following formulas i, ii and iii.
[0074]
[0075] Taking the preparation of the methyl-containing VHL derivative 6-((1-((2S, 4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)hexanoic acid as an example, the steps are as follows:
[0076] (i) Weigh 6-bromohexanoic acid (1.9 g, 10.0 mmol) into a 250 mL single-mouth bottle, add 30 mL of tetrahydrofuran to dissolve it, and then cool the system to -40 ° C. After the system is cooled, trifluoroacetic anhydride (6.2 g, 30.0 mmol) is slowly added dropwise thereto, and after stirring at -40 ° C for 30 min, the system is placed at room temperature, and tert-butyl alcohol (6.1 g, 80.0 mmol) is added dropwise during the slow heating process, and stirred for 18 h. After TLC confirms that the reaction is complete, the organic phase is concentrated, saturated sodium bicarbonate (50 mL) is added thereto, and extracted with EA (50 mL×3), the organic phases are combined, and dried over anhydrous sodium sulfate. After the organic phase is concentrated, it is purified by silica gel column with a mobile phase of petroleum ether: ethyl acetate = 50:1 (V / V) to obtain tert-butyl 6-bromohexanoate.
[0077] (ii) Weigh tert-butyl 6-bromohexanoate (251.0 mg, 1.0 mmol) in a 50 mL single-necked bottle and dissolve in acetonitrile (10 mL), add methylated VHL ligand (399.6 mg, 0.9 mmol), potassium carbonate (414.6 mg, 373.2 mmol), and potassium iodide (8.3 mg, 0.05 mmol), and then reflux the reaction at 85° C. overnight. After the reaction is complete as determined by TLC, extract with EA (30 mL×3) and water (30 mL), combine the organic phases, and dry over anhydrous sodium sulfate. The organic phase was concentrated and purified by silica gel column using mobile phase DCM:MeOH=60:1 (V / V) to give tert-butyl 6-((1-((2S,4R)-4-hydroxy-2-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)hexanoate.
[0078] (iii) tert-Butyl 6-((1-((2S,4R)-4-hydroxy-2-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)hexanoate (300 mg, 0.5 mmol) was placed in a 25 mL single-necked bottle, DCM (3 mL) was added thereto, trifluoroacetic acid (3 mL) was added dropwise to the system under ice bath, and then the system was warmed to room temperature and stirred for 3 h. After the reaction was completed as monitored by TLC, the solvent was concentrated to obtain 6-((1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)hexanoic acid.
[0079] The preparation methods of other alkyl chain VHL derivatives substituted with terminal carboxylic acid are the same as above.
[0080] [Example 2] Preparation of VHL derivatives with carboxylic acid-terminated double alkyl chains
[0081] The VHL derivative connected by a double alkyl chain with a carboxylic acid terminal is synthesized by the reaction shown in the following formula i, ii, iii.
[0082]
[0083] Taking the preparation of the methyl-bearing VHL derivative 6-((6-((1-((2S,4R)-4-hydroxy-2-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexyl)amine)hexanoic acid as an example, the steps are as follows:
[0084] (i) VHL (888 mg, 2.0 mmol) was weighed and placed in a 25 mL single-mouth bottle, DCM (10 mL) was added to dissolve it, and then N-Boc-6-aminocaproic acid (569.8 mg, 2.2 mmol), HATU (1.7 g, 4.4 mmol), and DIPEA (1.0 g, 8 mmol) were added to the system. The system was then stirred at room temperature for 3 h. After TLC confirmed that the reaction was complete, the organic phase was concentrated, saturated sodium bicarbonate (50 mL) was added thereto, and extracted with EA (50 mL×3), the organic phases were combined, and dried over anhydrous sodium sulfate. The organic phase was concentrated and purified by silica gel column with mobile phase DCM:MeOH=60:1 (V / V) to give tert-butyl ester of (6-((1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexyl)carbamate.
[0085] (ii) tert-Butyl (6-((1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexyl)carbamate (657.9 mg, 1.0 mmol) was placed in a 25 mL single-necked bottle and dissolved in DCM (10 mL). Trifluoroacetic acid (5 mL) was added dropwise to the system under ice bath, and then the system was heated to room temperature and stirred for 3 h. After the reaction was completed as monitored by TLC, the solvent was concentrated to obtain (2S,4R)-1-(2-(6-aminohexanamide)-3,3-dimethylbutyryl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide.
[0086] (iii) (2S, 4R)-1-(2-(6-aminohexanamide)-3,3-dimethylbutyryl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (502 mg, 0.9 mmol) was placed in a 25 mL single-mouth bottle, and acetonitrile (10 mL) was added thereto. Subsequently, tert-butyl 6-bromohexanoate (251.0 mg, 1.0 mmol), potassium carbonate (414.6 mg, 3 mmol), and potassium iodide (8.3 mg, 0.05 mmol) were added to the system. The reaction was then refluxed at 85° C. overnight. After the reaction was complete by TLC, EA (30 mL×3) and water (30 mL) were used for extraction, and the organic phases were combined and dried over anhydrous sodium sulfate. The organic phase was concentrated and purified by silica gel column with mobile phase DCM:MeOH=60:1 (V / V) to give tert-butyl 6-((6-((1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexyl)amino)hexanoate.
[0087] (iv) tert-Butyl 6-((6-((1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexyl)amino)hexanoate (364 mg, 0.5 mmol) was placed in a 25 mL single-necked bottle, DCM (3 mL) was added thereto, and ice was added. Trifluoroacetic acid (3 mL) was added dropwise to the system under a bath, and then the system was warmed to room temperature and stirred for 3 h. After the reaction was completed as monitored by TLC, the solvent was concentrated to give 6-((6-((1-((2S,4R)-4-hydroxy-2-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexyl)amine)hexanoic acid.
[0088] The preparation methods of other VHL derivatives connected by double alkyl chains with carboxylic acid at the ends are the same as above.
[0089] [Example 3] Preparation of alkyl chain VHL derivatives with bromine at the end
[0090] The VHL derivative having a double alkyl chain connected with a carboxylic acid terminal is synthesized by the reaction shown in the following formula i.
[0091]
[0092] Taking the preparation of the methyl-bearing VHL derivative (2S, 4R)-1-(2-(10-bromodecanamido)-3,3-dimethylbutyryl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide as an example, the steps are as follows:
[0093] VHL (888 mg, 2.0 mmol) was weighed and placed in a 25 mL single-mouth bottle, DCM (10 mL) was added to dissolve it, and then 10-bromodecanoic acid (555.2 mg, 2.2 mmol), HATU (836.5 g, 2.2 mmol), and DIPEA (1.0 g, 8 mmol) were added to the system. The system was then stirred at room temperature for 3 h. After TLC confirmed that the reaction was complete, the organic phase was concentrated, saturated sodium bicarbonate (50 mL) was added thereto, and EA (50 mL × 3) was used for extraction. The organic phases were combined and dried over anhydrous sodium sulfate. After the organic phase was concentrated, it was purified by silica gel column with mobile phase DCM: MeOH = 60:1 (V / V) to obtain (2S, 4R)-1-(2-(10-bromodecanamido)-3,3-dimethylbutyryl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide.
[0094] The preparation methods of other alkyl chain VHL derivatives with bromine at the end are the same as above.
[0095] [Example 4] Preparation of VHL derivatives with alkyl chains and alkoxy chains terminated with carboxylic acids
[0096] The alkyl chain and alkoxy chain chimeric VHL derivatives with carboxylic acid at the end are synthesized by the reactions shown in the following formulas i, ii, iii and iv.
[0097]
[0098] Taking the preparation of 3-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-2,2-dimethyl-17-oxo-7,10,13-trioxo-4,16-diazacyclohexane-20-oic acid as an example, the steps are as follows:
[0099] (i) Weigh succinic acid monoethyl ester (1.5 g, 10.0 mmol) into a 50 mL single-mouth bottle, add DCM (30 mL) to dissolve it, then add 2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethane-1-ol (2.1 g, 11.0 mmol), HATU (4.18 g, 11 mmol), and DIPEA (5.7 g, 8 mmol). Then, the system was stirred at room temperature for 3 h. After TLC confirmed that the reaction was complete, EA (30 mL×3) and water (30 mL) were extracted, and the organic phases were combined and dried over anhydrous sodium sulfate. After the organic phase was concentrated, it was purified by silica gel column with mobile phase DCM:MeOH=80:1 (V / V) to obtain ethyl-1-hydroxy-13-oxo-3,6,9-trioxo-12-hexadecanoic acid-16-ethyl ester.
[0100] (ii) Ethyl-1-hydroxy-13-oxo-3,6,9-trioxo-12-hexadecanoic acid-16-ethyl ester (642.7 mg, 2 mmol) was dissolved in DCM (15 mL), and then p-toluenesulfonic acid (300 mg, 1.16 mmol) and DIPEA (0.58 mL, 3.28 mmol) were added thereto at 0°C, and the system was warmed to room temperature for reaction for 12 h. After TLC confirmed that the reaction was complete, EA (30 mL×3) and water (30 mL) were extracted, and the organic phases were combined and dried over anhydrous sodium sulfate. After the organic phase was concentrated, it was purified by silica gel column with mobile phase DCM:MeOH=80:1 (V / V) to obtain Tos-substituted ethyl-1-hydroxy-13-oxo-3,6,9-trioxo-12-hexadecanoic acid-16-ethyl ester.
[0101] (iii) The product of the previous step (475.5 mg, 1 mmol) was dissolved in acetonitrile (10 mL). VHL (444.0 mg, 1.0 mmol), potassium carbonate (414.6 mg, 3 mmol), and potassium iodide (8.3 mg, 0.05 mmol) were then added to the system. The reaction was then refluxed at 85°C overnight. After TLC detection of the reaction was complete, EA (30 mL × 3) and water (30 mL) were extracted, the organic phases were combined, and dried over anhydrous sodium sulfate. The organic phase was concentrated and purified by silica gel column with mobile phase DCM: MeOH = 60:1 (V / V).
[0102] (iv) The product of the previous step was dissolved in EA (5 mL), and lithium hydroxide was added under ice bath until pH = 11. Then the temperature was raised to room temperature for reaction for 0.5 h. After TLC monitoring, the pH was adjusted to 3, and then EA (30 mL × 3) and water (30 mL) were used for extraction. The organic phases were combined and dried over anhydrous sodium sulfate. The organic phase was concentrated to obtain the product.
[0103] The preparation method of other VHL derivatives with alkyl chains or alkoxy chains having carboxylic acid at the end is the same as above.
[0104] [Example 5] Preparation of alkyl chain lenalidomide derivatives with carboxylic acid at the end
[0105] The terminal carboxylic acid-substituted alkyl chain pomalidomide or lenalidomide derivative is synthesized by the reactions shown in the following formulas i, ii, and iii.
[0106]
[0107] Taking the preparation of 6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindol-4-yl)amino)hexanoic acid as an example, the steps are as follows:
[0108] (i) Weigh 6-bromohexanoic acid (1.9 g, 10.0 mmol) into a 250 mL single-mouth bottle, add 30 mL of tetrahydrofuran to dissolve it, and then cool the system to -40 ° C. After the system is cooled, trifluoroacetic anhydride (6.2 g, 30.0 mmol) is slowly added dropwise thereto, and after stirring at -40 ° C for 30 min, the system is placed at room temperature, and tert-butyl alcohol (6.1 g, 80.0 mmol) is added dropwise during the slow heating process, and stirred for 18 h. After TLC confirms that the reaction is complete, the organic phase is concentrated, saturated sodium bicarbonate (50 mL) is added thereto, and extracted with EA (50 mL×3), the organic phases are combined, and dried over anhydrous sodium sulfate. After the organic phase is concentrated, it is purified by silica gel column with a mobile phase of petroleum ether: ethyl acetate = 50:1 (V / V) to obtain tert-butyl 6-bromohexanoate.
[0109] (ii) tert-Butyl 6-bromohexanoate (348.8 mg, 1.39 mmol) was dissolved in N-methylpyrrolidone (NMP) (5 mL), and then lenalidomide (300 mg, 1.16 mmol) and DIPEA (0.58 mL, 3.28 mmol) were added thereto, and the system was heated to 110° C. for 12 h. After the reaction was completed as monitored by TLC, saturated brine was added to the system, and the mixture was stirred for 5 min, filtered, and the solid was washed with water and dried to obtain tert-butyl 6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindol-4-yl)amino)hexanoate.
[0110] (iii) tert-Butyl 6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindol-4-yl)amino)hexanoate (429.5 mg, 1 mmol) was dissolved in dichloromethane (5 mL), trifluoroacetic acid (5 mL) was added under ice bath, and then the temperature was raised to room temperature for reaction for 3 h. After the reaction was completed as monitored by TLC, the organic solvent was concentrated to obtain 6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindol-4-yl)amino)hexanoic acid.
[0111] The preparation methods of other alkyl chain lenalidomide derivatives with carboxylic acid at the end are the same as above.
[0112] [Example 6] Preparation of alkyl chain benzodione piperidine derivatives with carboxylic acid at the end
[0113] The alkyl chain benzodione piperidine derivative substituted with terminal carboxylic acid is synthesized by the reactions shown in the following formulas i, ii, iii and iv.
[0114]
[0115] Taking the preparation of 11-(4-(2,6-dioxopiperidin-3-yl)phenoxy)undecanoic acid as an example, the steps are as follows:
[0116] (i) 2,6-bis(benzyloxy)-3-bromopyridine (100 mg, 0.27 mmol) was weighed and placed in a 25 mL single-mouth bottle, 1,4-dioxane (3 mL) and water (0.5 mL) were added to dissolve it, and then p-hydroxyphenylboric acid (74.5 mg, 0.54 mmol), potassium phosphate (123 mg, 0.58 mmol), and PdCl2(dppf) (22 mg, 0.027 mmol) were added to the system in sequence. The system was replaced with an argon atmosphere and stirred at 110°C for 16 h. After TLC confirmed that the reaction was complete, it was filtered with diatomaceous earth, and the obtained filtrate was diluted with EA (10 mL) and washed with saturated sodium chloride water (10 mL×3). The organic phase was dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column with a mobile phase of petroleum ether: ethyl acetate = 3:1 (V / V) to obtain 4-(2,6-bis(benzyloxy)pyridin-3-yl)phenol.
[0117] (ii) 4-(2,6-bis(benzyloxy)pyridin-3-yl)phenol (470 mg, 1.2 mmol) was dissolved in DMF (10 mL), and then anhydrous potassium carbonate (254.0 mg, 1.8 mmol) and 11-bromondecanoic acid (432 mg, 1.9 mmol) were added thereto in sequence, and the system was heated to 85°C for 12 h. After TLC confirmed that the reaction was complete, the mixture was filtered through diatomaceous earth, and the filtrate was diluted with EA (10 mL) and washed with saturated sodium chloride water (10 mL×3). The organic phase was dried over anhydrous sodium sulfate, concentrated, and purified through a silica gel column with a mobile phase of petroleum ether:ethyl acetate = 10:1 (V / V) to obtain tert-butyl 11-(4-(2,6-bis(benzyloxy)pyridin-3-yl)phenoxy)undecanoate.
[0118] (iii) 4-(4-(2,6-bis(benzyloxy)pyridin-3-yl)phenoxy)butyric acid tert-butyl ester (450.0 mg, 0.8 mmol) was dissolved in anhydrous ethanol (5 mL) and 10% Pd / C (40 mg) was slowly added. Then the system was replaced with hydrogen and a hydrogen balloon was added. The system was placed at room temperature to react for 12 h. After TLC monitoring, the reaction was completed and filtered through diatomaceous earth. The filtrate was extracted with EA (10 mL×3), and the organic phases were combined and dried over anhydrous sodium sulfate. After the organic phase was concentrated, it was purified by silica gel column with mobile phase of petroleum ether: ethyl acetate = 3:1 (V / V) to obtain 11-(4-(2,6-dioxopiperidin-3-yl)phenoxy)undecanoic acid tert-butyl ester.
[0119] (iii) tert-Butyl 4-(4-(2,6-dioxopiperidin-3-yl)phenoxy)butanoate (300 mg, 0.9 mmol) was dissolved in DCM (3 mL), trifluoroacetic acid (3 mL) was slowly added dropwise under ice bath and stirred at room temperature for 3 h. After the reaction was complete as monitored by TLC, the mixture was filtered through celite and the organic phase was concentrated to obtain 11-(4-(2,6-dioxopiperidin-3-yl)phenoxy)undecanoic acid.
[0120] The preparation methods of other alkyl chain benzodione piperidine derivatives with carboxylic acid at the end are the same as above.
[0121] [Example 7] Preparation of alkyl chain 9-aminofluorene derivatives with carboxylic acid at the end
[0122] The alkyl chain 6-((9H-fluoren-9-yl)amino)hexanoic acid having a terminal carboxylic acid substituted is synthesized by the reaction shown in the following formula i and ii.
[0123]
[0124] (i) Take 9-aminofluorene (400.0 mg, 2.2 mmol) and dissolve it in acetonitrile (10 mL). Then add tert-butyl 6-bromohexanoate (607.4 mg, 2.4 mmol), potassium carbonate (910.8 mg, 6.6 mmol), and potassium iodide (18.3 mg, 0.11 mmol) to the system. Then place the reaction at 85 ° C. reflux overnight. After TLC detection, EA (30 mL × 3) and water (30 mL) are extracted, and the organic phases are combined and dried over anhydrous sodium sulfate. After the organic phase is concentrated, it is purified by silica gel column with mobile phase petroleum ether: EA = 3:1 (V / V) to obtain tert-butyl 6-((9H-fluoren-9-yl)amino)hexanoate.
[0125] (ii) Dissolve tert-butyl 6-((9H-fluoren-9-yl)amino)hexanoate (500 mg, 1.4 mol) in DCM (3 mL), cool the system to 0°C, and stir for 5 min. Slowly add trifluoroacetic acid (3 mL) dropwise to the system under an ice bath, then warm the system to room temperature and stir for 1 h. After the reaction is complete as monitored by TLC, concentrate the system to obtain 6-((9H-fluoren-9-yl)amino)hexanoic acid.
[0126] [Example 8] Preparation of alkyl chain RNF-114 ligand derivatives with carboxylic acid at the end
[0127] The alkyl chain 11-(4-(3-(4-bromophenyl)-1-(2-chloroacetyl)-4,5-dihydro-1H-pyrazol-5-yl)phenoxy)undecanoic acid substituted with terminal carboxylic acid is synthesized by the reactions shown in the following formulas i, ii, iii and iv.
[0128]
[0129] (i) A sodium hydroxide aqueous solution (10%, 10 mL) was added to a mixture of p-hydroxyacetophenone (1.9 g, 16 mol) and 4-hydroxybenzaldehyde (3.14 g, 16 mmol) in ethanol (5 mL), and the reaction was then allowed to react at room temperature for 24 h. After the reaction was complete, the pH of the solution was adjusted to 7 with hydrochloric acid (10%), and the precipitate was filtered, rinsed with water, and dried. The obtained solid was recrystallized from ethanol and water to obtain pure (E)-1-(4-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one.
[0130] (ii) (E)-1-(4-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one (200 mg, 0.7 mmol) was dissolved in dry DMF, and then tert-butyl 11-bromondecanoate (354 mg, 1.1 mmol) and potassium carbonate (366 mg, 2.8 mmol) were added thereto. The system was replaced with argon and stirred at 60°C for 5 h. After TLC confirmed that the reactants were completely consumed, the system was cooled to room temperature, the insoluble potassium carbonate was filtered out, and then extracted with EA (50 mL×3), the organic phases were combined and washed with saturated sodium chloride water, dried over anhydrous sodium sulfate, and the solvent was concentrated in vacuo and then purified by column chromatography (PE:EA=4:1) to obtain tert-butyl (E)-11-(4-(3-(4-bromophenyl)-3-oxopropan-1-yl)phenoxy)undecanoate.
[0131] (iii) Tert-butyl (E)-11-(4-(3-(4-bromophenyl)-3-oxopropan-1-yl)phenoxy)undecanoate (200 mg, 0.7 mmol) was dissolved in anhydrous ethanol, and then hydrazine hydrate (175.2 mg, 3.5 mmol) was added thereto, the system was replaced with argon, and stirred at 80°C for 5 h. After TLC confirmed that the reactant was completely consumed, the system was cooled to room temperature, quenched with water and extracted with DCM (10 mL×3). The organic phases were combined and concentrated to about 5 mL. Then, chloroethanesulfonyl chloride (117.9 mg, 1 mmol) and triethylamine (211.1 mg, 2.08 mmol) were quickly added thereto under an ice bath, the system was replaced with argon, stirred for 0.5 h, and then the system was warmed to room temperature and stirred overnight. After TLC confirmed that the reaction was complete, it was extracted with EA (50 mL×3), the organic phases were combined and washed with saturated sodium chloride water, dried over anhydrous sodium sulfate, and the solvent was concentrated in vacuo and then purified by column chromatography (PE:EA=3:1) to give tert-butyl 11-(4-(3-(4-bromophenyl)-1-(2-chloroacetyl)-4,5-dihydro-1H-pyrazol-5-yl)phenoxy)undecanoate.
[0132] (iv) tert-Butyl 11-(4-(3-(4-bromophenyl)-1-(2-chloroacetyl)-4,5-dihydro-1H-pyrazol-5-yl)phenoxy)undecanoate (310 mg, 0.5 mmol) was dissolved in DCM (3 mL), trifluoroacetic acid (3 mL) was added thereto under ice bath, and the system was warmed to room temperature and stirred for 3 h. After TLC confirmed that the reactant was completely consumed, the solvent was concentrated in vacuo to give 11-(4-(3-(4-bromophenyl)-1-(2-chloroacetyl)-4,5-dihydro-1H-pyrazol-5-yl)phenoxy)undecanoic acid.
[0133] [Example 9] Preparation of PROTAC compounds of series I remdesivir
[0134] The PROTAC compound of series I remdesivir was synthesized by the reaction shown in formula i below.
[0135]
[0136] Taking the preparation of the compound 2-ethylbutyl((S)-(((2R,3S,4R,5R)-5-cyano-3,4-dihydroxy-5-(4-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)hexylamino)pyrrolo[2,1-f][1,2,4]triazine-7-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate as an example, the steps are as follows:
[0137] Weigh remdesivir (200 mg, 0.33 mmol), (S)-7-((2S, 4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-8,8-dimethylnonyl acid (197.4 mg, 0.363 mmol), HATU (138.0 g, 0.363 mmol), DIPEA (159 mg, 1.32 mmol). The system was then stirred at room temperature for 3 h. After TLC confirmed that the reaction was complete, the organic phase was concentrated, saturated sodium bicarbonate (10 mL) was added thereto, extracted with EA (10 mL×3), the organic phases were combined, and dried over anhydrous sodium sulfate. The organic phase was concentrated and purified by silica gel column with mobile phase DCM:MeOH=40:1 (V / V) to give 2-ethylbutyl((S)-(((2R,3S,4R,5R)-5-cyano-3,4-dihydroxy-5-(4-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)hexylamino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate.
[0138] The preparation methods of other series I compounds are the same as above.
[0139] [Example 10] Preparation of PROTAC compounds of series II GS-441524
[0140] The PROTAC compound of series II GS-441524 was synthesized by the reaction shown in formula i below.
[0141]
[0142] Taking the preparation of the compound ethyl (2S, 4R)-1-((S)-2-((6-((7-((2R, 3R, 4S, 5R)-2-cyano-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrrolo[2,1-f][1,2,4]triazine-4-yl)amino)-6-oxohexyl)amino)-3,3-dimethylbutyryl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide as an example, the steps are as follows:
[0143] GS-441524 (300 mg, 1.0 mmol), (S)-7-((2S, 4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-8,8-dimethylnonyl acid (543.1 mg, 1.1 mmol), HATU (418.3 mg, 1.1 mmol), DIPEA (516.0 mg, 4 mmol) were weighed. The system was then stirred at room temperature for 3 h. After TLC confirmed that the reaction was complete, the organic phase was concentrated, saturated sodium bicarbonate (10 mL) was added thereto, extracted with EA (10 mL×3), the organic phases were combined, and dried over anhydrous sodium sulfate. After the organic phase was concentrated, it was purified by silica gel column with mobile phase DCM:MeOH=40:1 (V / V) to obtain the compound ethyl (2S,4R)-1-((S)-2-((6-((7-((2R,3R,4S,5R)-2-cyano-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-6-oxohexyl)amino)-3,3-dimethylbutyryl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide.
[0144] The preparation methods of other series II compounds are the same as above.
[0145] [Example 11] Series III (1) Preparation of PROTAC compounds of GS-441524
[0146] The PROTAC compound of series III (1) GS-441524 was synthesized by the reaction shown in the following formula i and ii.
[0147]
[0148] Taking the preparation of ((2R, 3S, 4R, 5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl 6-(((S)-1-((2S, 4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)hexanoate as an example, the steps are as follows:
[0149] (i) The 2'-OH, 3'-OH protected GS-441524 intermediate (331.1 mg, 1.0 mmol) was dissolved in DCM (5 mL), and then (S)-7-((2S, 4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-8,8-dimethylnonyl acid (543.1 mg, 1.1 mmol), EDCI (210.87 mg, 1.1 mmol), and DMAP (146.6 mg, 1.2 mmol) were added to the system in sequence, and the reaction was carried out at room temperature for 3 h. After TLC confirmed that the reaction was complete, the mixture was extracted with EA (10 mL×3) and water (10 mL), and the organic phases were combined and dried over anhydrous sodium sulfate. After the organic phase was concentrated, it was purified by silica gel column with mobile phase DCM:MeOH=40:1 (V / V) to obtain the compound ((3aR,4R,6R,6aR)-6-(4-aminopyrrole[2,1-f][1,2,4]triazine-7-yl)-6-cyano-2,2-dimethyltetrahydrofuran[3,4-d][1,3]dioxin-4-yl)methyl 6-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)hexanoate.
[0150] (ii) The product obtained in the previous step was dissolved in THF (1.5 mL), and concentrated hydrochloric acid (0.3 mL) was slowly added dropwise to the system under ice-cooling, and then the mixture was warmed to room temperature and stirred for 3 h. After the reactants were completely consumed as monitored by TLC, saturated sodium bicarbonate (5 mL) was added to the system until pH = 7, followed by extraction with EA (10 mL×3), the organic phases were combined and dried over anhydrous sodium sulfate, and then concentrated to give ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl 6-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)hexanoate
[0151] The preparation methods of other series III(1) compounds are the same as above.
[0152] [Example 12] Series III (2) Preparation of PROTAC compounds of GS-441524
[0153] The PROTAC compound of series III (2) GS-441524 was synthesized by the reaction shown in the following formula i and ii.
[0154]
[0155] The method used in this series is the same as that used to prepare the PROTAC compound of series III (1) GS-441524 in Example 11, with only the chirality of the VHL derivative being different.
[0156] [Example 13] Series III (3) Preparation of PROTAC compounds of GS-441524
[0157] The PROTAC compound of series III (3) GS-441524 was synthesized by the reaction shown in formula i below.
[0158]
[0159] Taking the preparation of the compound (2S,4R)-1-((S)-2-(10-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)decanamine)-3,3-dimethylbutyryl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide as an example, the steps are as follows:
[0160] (i) The 2'-OH, 3'-OH protected GS-441524 intermediate (331.1 mg, 1.0 mmol) was dissolved in acetonitrile (5 mL), and then (2S, 4S)-1-(2-(10-bromodecylamido)-3,3-dimethylbutyryl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (745.5 mg, 1.1 mmol), anhydrous potassium carbonate (414 mg, 3 mmol), and potassium iodide (8.3 mg, 0.05 mmol) were added thereto in sequence. The system was placed at 85° C. for 12 h. After TLC confirmed that the reactants were completely consumed, the system was cooled to room temperature, EA (20 mL) was added thereto, and then extracted with EA (20 mL×3) and water (20 mL). The organic phases were combined and dried over anhydrous sodium sulfate, concentrated and purified by column chromatography (DCM:MeOH=40:1) to give (2S,4S)-1-(2-(10-(((3aR,4R,6R,6aR)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-6-cyano-2,2-dihydroxytetrahydrofuran[3,4-d][1,3]dioxolan-4-yl)methoxy)decylamide)-3,3-dimethylbutyryl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide
[0161] (ii) The method used is the same as the preparation method (ii) of compound III(1) in Example 11.
[0162] The preparation methods of other series III (3) compounds are the same as above.
[0163] [Example 14] Series IV (1) Preparation of PROTAC compounds of GS-441524
[0164] The PROTAC compounds of series IV (1) remdesivir and GS-441524 were synthesized by the reactions shown in the following formulas i and ii.
[0165]
[0166] The preparation method of this series of compounds is the same as the preparation of the PROTAC compound of series III (1) GS-441524 in Example 11, except that the VHL derivative is replaced by a CRBN derivative.
[0167] [Example 15] Series IV (2) Preparation of PROTAC compounds of GS-441524
[0168] The PROTAC compounds of series IV (2) remdesivir and GS-441524 were synthesized by the reactions shown in the following formulas i and ii.
[0169]
[0170] The preparation method of this series of compounds is the same as the preparation of the PROTAC compound of series III (1) GS-441524 in Example 11, except that the VHL derivative is replaced by a benzodione piperidine derivative.
[0171] [Example 16] Series V (1) Preparation of PROTAC compounds of GS-441524
[0172] The PROTAC compounds of series V(1) GS-441524 were synthesized by the reactions shown in the following formulas i, ii, and iii.
[0173]
[0174] Taking the preparation of the compound ((2R, 3S, 4R, 5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)6-((S)-2,6-bis((tert-butyloxycarbonyl)amino)hexylamino)hexanoate as an example, the steps are as follows:
[0175] (i) 2'-OH, 3'-OH protected GS-441524 intermediate (331.1 mg, 1.0 mmol) was dissolved in DCM (15 mL), and then N-Boc-6-aminocaproic acid (254.1 mg, 1.1 mmol), EDCI (210.87 mg, 1.1 mmol), and DMAP (146.6 mg, 1.2 mmol) were added to the system in sequence, and reacted at room temperature for 3 h. After TLC confirmed that the reaction was complete, it was extracted with EA (10 mL×3) and water (10 mL), and the organic phases were combined and dried over anhydrous sodium sulfate. After the organic phase was concentrated, it was purified by silica gel column with mobile phase DCM:MeOH=80:1 (V / V) to obtain the compound ((3aR,4R,6R,6aR)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-6-cyano-2,2-dimethyltetrahydrofuran[3,4-d][1,3]dioxolan-4-yl)6-((tert-butoxycarbonyl)amino)hexanoic acid methyl ester.
[0176] (ii) Methyl ((3aR, 4R, 6R, 6aR)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-6-cyano-2,2-dimethyltetrahydrofuran[3,4-d][1,3]dioxolan-4-yl)6-((tert-butyloxycarbonyl)amino)hexanoate (544.6 mg, 1 mmol) was placed in a 5 mL single-necked flask, and then 4 mL of tetrahydrofuran was added to the system and the system was placed in an ice bath for 5 min. After the system temperature dropped to 0°C, concentrated hydrochloric acid (0.6 mL) was slowly added dropwise to the system, and then the reaction was placed at room temperature for 3 h. After TLC confirmed that the reaction was complete, saturated sodium bicarbonate (5 mL) was added to the system to quench the reaction and extracted with EA (10 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated in vacuo to obtain ((2R, 3S, 4R, 5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl) 6-aminohexanoic acid methyl ester.
[0177] (iii) Methyl ((2R, 3S, 4R, 5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl) 6-aminohexanoate (300 mg, 0.7 mmol) was placed in a 10 mL single-necked bottle, and then Boc-lysine (266.4 mg, 0.77 mmol), HATU (292.8 mg, 0.8 mmol), and DIPEA (361.2 mg, 2.8 mmol) were added to the reaction, and the system was reacted at room temperature for 3 h. After TLC confirmed that the reaction was complete, the mixture was extracted with EA (10 mL×3) and water (10 mL), and the organic phases were combined and dried over anhydrous sodium sulfate. After the organic phase was concentrated, it was purified by silica gel column with mobile phase DCM:MeOH=80:1 (V / V) to obtain ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)6-((S)-2,6-bis((tert-butoxycarbonyl)amino)hexylamino)hexanoate compound.
[0178] The preparation of the remaining PROTAC compounds of series V(1) GS-441524 was the same as above.
[0179] [Example 17] Preparation of PROTAC compounds of series V (2) GS-441524
[0180] ((2R, 3S, 4R, 5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)6-((9H-fluoren-9-yl)amino)hexanoate is synthesized by the reaction shown in the following formula i and ii.
[0181]
[0182] The preparation method of this series of compounds is the same as the preparation of the PROTAC compound of series III (1) GS-441524 in Example 11, except that the VHL derivative is replaced by a 9-aminofluorene derivative.
[0183] [Example 18] Series V (3) PROTAC compounds of GS-441524
[0184] ((2R, 3S, 4R, 5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl 11-(4-(3-(4-bromophenyl)-1-(2-chloroacetyl)-4,5-dihydropyrazol-5-yl)phenoxy)undecanoate was synthesized by the reaction shown in the following formula i and ii.
[0185]
[0186] The preparation method of this series of compounds is the same as the preparation of the PROTAC compound of series III (1) GS-441524 in Example 11, except that the VHL derivative is replaced by the RNF-114 ligand derivative.
[0187] (1) Compound numbered R-1 in Table 1
[0188] The target compound was prepared by referring to the method in Example 9. The product was a white solid with a yield of 55%.
[0189] 1 HNMR (400MHz, Methanol-d4) δ8.89 (s, 1H), 7.88 (s, 1H), 7.46–7.40 (m, 4H), 7.33–7.26 (m, 2H), 7.20–7.13 (m, 3H), 6.95–6.89 (m, 2H), ( m, 2H), 4.07–4.01 (m, 1H), 3.97–3.91 (m, 1H), 3.90–3.83 (m, 1H), 3.77 (d, J = 11.2Hz, 1H), 3.71–3.64 (m, 1H), 3.27–3.22 (m, 1H), 2.48 (s , 6H), 2.26–2.20(m, 1H), 2.02–1.94(m, 1H), 1.77–1.69(m, 2H), 1.56–1.43(m, 8H), 1.34–1.28(m, 9H), 1.04(s, 9H), 0.90–0.86(m, 6H). 13C NMR (101MHz, Methanol-d4) δ173.03, 171.99, 155.83, 151.47, 150.69, 147.66, 147.04, 146.91, 144.23, 131.96, 130.10, 129.34, 129.19, 129.10, 129.08, 126.24, 124.70, 119.98, 119.94, 119.93, 119.89, 116.84, 116.54, 116. 20, 111.37, 110.91, 101.23, 80.43, 79.20, 74.83, 72.96, 72.12, 70.24, 69.55, 67.00, 66.73, 59.04, 56.51, 50.62, 48.75, 40.29, 37.14, 34.74, 33.45, 29.35, 26.30, 25.94, 24.45, 22.84, 22.82, 21.07, 19.10, 14.43, 9.98, 9.93.
[0190] (2) Compound numbered R-2 in Table 1
[0191] The target compound was prepared by referring to the method in Example 9. The product was a white solid with a yield of 59%.
[0192] 1 H NMR (400MHz, Methanol-d4) δ8.89(s,1H), 7.89(d,J=2.0Hz,1H), 7.44(d,J=2.5Hz,4H), 7.28(ddd,J=9.5,5 .9,2.2Hz,2H), 7.19–7.11(m,3H), 6.95–6.89(m,2H), 5.37–5.32(m,1H), 5.15(d,J=5.8Hz,1H), 5.03(t,J= 6.8Hz, 2H), 4.71–4.63 (m, 2H), 4.56 (qd, J=4.0, 1.6Hz, 1H), 4.46 (d, J=4.7Hz, 2H), 4.43–4.32 (m, 3H), 4.08 –4.00(m,1H), 3.98–3.92(m,1H), 1.71(q,J=7.3Hz,2H), 1.53(dd,J=12.8,7.1Hz,6H), 1.37–1.30(m,13H). 13C NMR (101MHz, Methanol-d4) δ173.50,173.07,171.94,155.87,151.48,150.62,147.65,147.04,144.22,131.96,130. 47,129.34,129.09,126.25,124.71,123.21,119.98,119.52,116.85,116.18,111.43,110.92,101.25,83.19,81.78, 80.24,79.18,74.27,72.92,72.16,70.24,69.55,66.92,66.74,65.45,59.05,56.56,54.33,50.08,48.75,40.29,37.18,34.74,33.51,30.78,29.36,28.72,28.56,28.46,26.53,25.94,24.40,22.81,21.08,19.12,14.46,10.00,9.58.
[0193] (3) Compound numbered R-3 in Table 1
[0194] The target compound was prepared by referring to the method in Example 9. The product was a white solid with a yield of 53%.
[0195] 1HNMR (400MHz, Methanol-d4) δ8.89 (s, 1H), 7.87 (s, 1H), 7.47–7.39 (m, 4H), 7.33–7.25 (m, 2H), 7.23–7.12 (m, 3H), 6.96–6.88 (m, 2H), 5.35 (dd , J=5.8, 4.0Hz, 1H), 5.15 (d, J=5.8Hz, 1H), 5.03–4.99 (d, J=7.0Hz, 1H), 4.70–4.63 (m, 2H), 4.60–4.52 (m, 1H), 4.45 (s, 1H), 4.42–4.39 (m, 2H) , 4.10–4.01 (m, 1H), 3.98–3.91 (m, 1H), 3.90–3.81 (m, 1H), 3.76 (d, J=11.2Hz, 1H), 3.67 (dd, J=11.4, 3.8Hz, 1H), 3.24 (s, 1H), 2.54–2.44 (m, 6 H), 2.27–2.16(m, 1H), 2.03–1.93(m, 1H), 1.77–1.66(m, 2H), 1.56–1.4 4(m, 6H), 1.41–1.24(m, 15H), 1.03(d, J=6.3Hz, 9H), 0.90–0.84(m, 6H). 13 C NMR (101MHz, Methanol-d4) δ173.53, 171.98, 157.92, 152.16, 150.69, 147.66, 146.92, 146.40, 143.38, 131.96, 130.11, 129.34, 129.09, 126.25, 124.70, 123.22, 119.98, 119.95, 119.90, 116.85, 116.53, 116.15, 111.45, 110 .92, 101.24, 79.87, 79.20, 74.27, 72.91, 72.17, 70.25, 69.53, 67.04, 66.75, 59.02, 56.51, 50.09, 48.74, 40.30, 37.15, 34.72, 33.93, 33.52, 29.34, 28.68, 28.62, 26.72, 25.96, 24.43, 22.82, 21.60, 19.51, 14.45, 9.99, 9.04.
[0196] (4) Compound numbered R-4 in Table 1
[0197] The target compound was prepared by referring to the method in Example 9. The product was a white solid with a yield of 53%.
[0198] 1 HNMR (400MHz, Methanol-d4) δ8.89 (d, J=2.0Hz, 1H), 7.91–7.84 (m, 1H), 7.47–7.40 (m, 4H), 7.33–7.25 (m, 2H), 7.21–7.10 (m, 3H), 6.95–6.88 (m, 2H) ), 5.35(dd, J=5.8, 3.9Hz, 1H), 5.14(dd, J=8.2, 5.7Hz, 1H), 5.05–4.98(d , J=7.0Hz, 1H), 4.68 (d, J=8.4Hz, 1H), 4.57–4.52 (m, 1H), 4.48–4.43 (m, 1H) ), 4.41–4.31(m, 2H), 4.08–4.00(m, 1H), 3.97–3.92(m, 1H), 3.91–3.82(m , 1H), 3.76 (d, J=11.3Hz, 1H), 3.70–3.65 (m, 1H), 3.28 (s, 1H), 2.54–2.46 (m, 6H), 2.27–2.18 (m, 1H), 2.03–1.93 (m, 1H), 1.76–1.67 (m, 2H), 1.56–1 .45(m, 6H), 1.37–1.29(m, 17H), 1.04(d, J=3.8Hz, 9H), 0.90–0.86(m, 6H). 13 C NMR (101MHz, Methanol-d4) δ175.29, 173.10, 170.92, 155.50, 150.63, 148.27, 147.03, 142.61, 131.96 , 130.11, 129.34, 129.21, 129.10, 126.72, 124.70, 123.72, 120.98, 119.96, 119.91, 112.25, 102.50, 8 1.77, 79.23, 72.89, 72.18, 69.53, 67.02, 66.74, 59.03, 56.53, 50.08, 48.74, 40.30, 37.19, 35.86, 33.54, 30.78, 29.36, 28.92, 28.86, 28.67, 26.84, 25.95, 23.95, 22.85, 21.49, 19.12, 14.46, 10.00, 9.95.
[0199] (5) Compound numbered R-5 in Table 1
[0200] The target compound was prepared by referring to the method in Example 9. The product was a white solid with a yield of 40%.
[0201] 1HNMR (400MHz, Methanol-d4) δ8.89 (s, 1H), 7.87 (s, 1H), 7.49–7.41 (m, 4H), 7.33–7.25 (m, 2H), 7.23–7.12 (m, 3H), 6.94–6.89 (dd, J=11.7, 4. 6Hz, 2H), 5.35 (dd, J=5.8, 3.9Hz, 1H), 5.14 (d, J=5.8Hz, 1H), 5.03 (s, 1H), 4.68–4.63 (s, 2H), 4.57–4.52 (m, 1H), 4.48–4.45 (m, 1H), 4.41–4.3 0 (m, 2H), 4.07–4.01 (m, 1H), 3.97–3.92 (m, 1H), 3.90–3.81 (m, 1H), 3.76 (d, J=11.3Hz, 1H), 3.67 (dd, J=11.2, 3.6Hz, 1H), 3.25 (s, 1H), 2.54–2 .45(m, 6H), 2.26–2.18(m, 1H), 2.03–1.94(m, 1H), 1.75–1.66(m, 2H), 1 .59–1.46(m, 6H), 1.38–1.28(m, 19H), 1.04(s, 9H), 0.90–0.85(m, 6H). 13 C NMR (101MHz, MeOD) δ173.89, 173.01, 168.65, 151.48, 147.66, 146.74, 142.63, 131.96, 130.02, 129 .33, 129.22, 129.10, 125.61, 124.70, 119.94, 119.49, 115.71, 108.50, 101.24, 80.15, 78.61, 74.37 , 72.89, 72.17, 69.52, 67.06, 66.74, 58.65, 56.50, 50.08, 48.74, 39.76, 37.16, 35.18, 33.53, 29.35, 29.09, 28.90, 28.72, 26.93, 25.95, 24.47, 22.84, 22.81, 20.66, 19.01, 18.50, 14.43, 10.41, 9.94.
[0202] (6) Compound numbered R-6 in Table 1
[0203] The target compound was prepared by referring to the method in Example 9. The product was a white solid with a yield of 34%.
[0204] 1HNMR (400MHz, Methanol-d4) δ8.90 (s, 1H), 7.87 (s, 1H), 7.46–7.43 (m, 4H), 7.34–7.24 (m, 2H), 7.24–7.12 (m, 3H), 6.97–6.86 (m, 2H), 5.37 (dd, J= 5.7, 4.1Hz, 1H), 5.13 (d, J=5.7Hz, 1H), 5.04–4.98 (m, 1H), 4.65–4.56 (m, 2H), 4.46(s, 1H), 4.40–4.30(m, 3H), 4.28–4.14(m, 3H), 4.06–4.00(m, 1H ), 3.96–3.84(m, 3H), 3.79–3.65(m, 10H), 3.58–3.54(m, 2H), 3.40(t, J=5 .4Hz, 2H), 2.79–2.75 (m, 1H), 2.73–2.64 (m, 3H), 2.50 (d, J=2.4Hz, 5H), 2 .26–2.18 (m, 2H), 2.00–1.94 (m, 1H), 1.52 (dd, J=7.0, 2.3Hz, 3H), 1.37–1 .33(m, 4H), 1.27(d, J=7.1Hz, 3H), 1.07–1.04(m, 9H), 0.90–0.85(m, 6H). 13 C NMR (101MHz, Methanol-d4) δ172.92, 172.35, 171.85, 171.22, 158.09, 152.23, 148.79, 146.29, 144.91, 131 .96, 130.67, 129.33, 128.73, 126.23, 124.69, 119.92, 116.83, 110.98, 110.91, 109.99, 109.20, 100.82, 79. 86, 78.60, 73.83, 73.14, 72.10, 70.43, 69.86, 69.60, 69.07, 66.70, 63.60, 58.49, 56.43, 50.08, 48.74, 40.29, 38.78, 37.40, 35.20, 30.87, 29.35, 28.86, 27.71, 25.82, 25.57, 22.82, 20.19, 18.98, 15.30, 13.24, 9.33.
[0205] (7) Compound numbered R-7 in Table 1
[0206] The target compound was prepared by referring to the method in Example 9. The product was a white solid with a yield of 42%.
[0207] 1 HNMR (400MHz, Methanol-d4) δ8.90 (d, J=1.9Hz, 1H), 7.90 (s, 1H), 7.45–7.43 (m, 4H), 7.35–7.25 (m, 2H), 7.19–7.13 (m, 3H), 6.95–6.88 (m, 2H), 5.35 (d d, J=5.8, 3.9Hz, 1H), 5.14 (d, J=5.8Hz, 1H), 5.05–4.98 (m, 1H), 4.67 (s, 1H) , 4.63–4.56(m, 2H), 4.46(s, 2H), 4.41–4.33(m, 3H), 4.23–4.16(m, 3H), 4.0 7–4.01(m, 1H), 3.97–3.83(m, 4H), 3.79–3.65(m, 9H), 3.56–3.52(m, 2H), 3. 40–3.35(m, 2H), 2.51–2.48(m, 5H), 2.28–2.21(d, J=11.9Hz, 4H), 2.01–1.9 2 (m, 2H), 1.74–1.72 (m, 2H), 1.68–1.61 (m, 2H), 1.52 (d, J=5.0Hz, 3H), 1.36 –1.34 (d, J=3.8Hz, 4H), 1.29–1.26 (m, 3H), 1.05 (s, 9H), 0.90–0.85 (m, 6H). 13 C NMR (101MHz, Methanol-d4) δ193.78, 172.66, 171.85, 171.19, 157.53, 155.74, 152.57, 147.65, 146.89, 142.94, 137 .20, 131.96, 130.09, 129.33, 129.09, 128.37, 126.23, 124.70, 123.23, 119.46, 111.27, 102.51, 79.12, 72.94, 72.19 , 70.18, 70.11, 69.86, 69.59, 69.18, 66.70, 63.69, 59.57, 59.19, 56.47, 49.94, 49.32, 46.51, 40.30, 38.99, 36.78, 35.26, 33.14, 31.45, 29.36, 25.58, 24.90, 23.93, 22.83, 22.81, 22.34, 21.04, 19.03, 14.42, 12.74, 9.98, 9.27, 7.83.
[0208] (8) Compound numbered R-8 in Table 1
[0209] The target compound was prepared by referring to the method in Example 9. The product was a white solid with a yield of 45%.
[0210] 1 HNMR (400MHz, Methanol-d4) δ8.89 (s, 1H), 7.89 (s, 1H), 7.46–7.43 (m, 4H), 7.33–7.24 (m, 2H), 7.22–7.12 (m, 3H), 6.92 (q, J=4.7Hz, 2H), 5.35 (dd, J=5.8 , 3.9Hz, 1H), 5.13 (d, J=5.8Hz, 1H), 5.04–4.95 (m, 1H), 4.70–4.59 (m, 2H), 4 .55(dd, J=4.2, 1.7Hz, 1H), 4.51–4.41(m, 2H), 4.40–4.33(m, 3H), 4.28–4.15 (m, 3H), 4.07–4.01 (m, 1H), 3.99–3.80 (m, 4H), 3.75–3.64 (m, 9H), 3.55 (t, J =5.3Hz, 2H), 3.40–3.35(m, 2H), 2.49(s, 5H), 2.22(t, J=7.3Hz, 4H), 2.02–1. 92(m, 1H), 1.72(t, J=7.3Hz, 2H), 1.67–1.56(m, 4H), 1.52(d, J=7.1Hz, 3H), 1 .41–1.35(m, 6H), 1.28(d, J=7.1Hz, 3H), 1.05(s, 9H), 0.88(t, J=7.4Hz, 6H). 13C NMR (101MHz, Methanol-d4) δ175.61, 174.20, 172.99, 172.25, 171.23, 157.16, 154.81, 151.50, 150.24, 148.11, 147.07, 144.25, 131.46, 130.09, 129.35, 128.37, 126.86, 125.12, 123.25, 119.95, 119.90, 117.26, 115.28, 112.38, 101.25, 82.6 2, 79.11, 72.97, 72.18, 70.11, 70.06, 69.85, 69.60, 69.34, 68.54, 66.73, 63.48, 59.62, 59.21, 56.59, 50.08, 49.35, 40.29, 38.94, 37.41, 36.01, 35.23, 33.48, 28.43, 28.37, 25.59, 25.43, 24.34, 23.30, 21.84, 19.09, 19.02, 15.48, 9.99, 9.94.
[0211] (9) Compound numbered R-12 in Table 1
[0212] The target compound was prepared by referring to the method in Example 14. The product was a white solid with a yield of 33%.
[0213] 1 HNMR (400MHz, Methanol-d4) δ8.88 (s, 1H), 7.88 (d, J=7.1Hz, 1H), 7.44 (s, 4H), 6.92 (q, J =4.5Hz, 2H), 5.09–5.01(m, 1H), 4.89(s, 1H), 4.68(q, J=6.5, 4.7Hz, 1H), 4.52–4.29(m, 4H ), 4.22–4.14(m, 1H), 3.81–3.65(m, 2H), 3.25(s, 1H), 2.49(s, 5H), 2.40–2.17(m, 4H), 2. 04–1.96 (m, 1H), 1.54 (dd, J=13.1, 6.8Hz, 5H), 1.37–1.16 (m, 12H), 1.04 (d, J=5.2Hz, 9H). 13C NMR (101MHz, Methanol-d4) δ173.69, 172.00, 155.40, 151.97, 148.07, 146. 96, 144.23, 131.97, 130.08, 126.26, 122.09, 116.32, 102.48, 81.99, 79.99 ,74.70,70.67,69.55,66.58,61.92,59.04,56.54,48.76,48.28,36.78,34 .73, 33.12, 29.36, 29.07, 28.86, 28.66, 26.93, 25.99, 24.57, 22.57, 15.40.
[0214] (10) Compound numbered R-13 in Table 1
[0215] The target compound was prepared by referring to the method in Example 14. The product was a white solid with a yield of 53%.
[0216] 1 HNMR (400MHz, Methanol-d4) δ8.88 (s, 1H), 7.88 (d, J=7.1Hz, 1H), 7.44 (s, 4H), 6.92 (q, J =4.5Hz, 2H), 5.09–5.01(m, 1H), 4.89(s, 1H), 4.68(q, J=6.5, 4.7Hz, 1H), 4.52–4.29(m, 4H ), 4.22–4.14(m, 1H), 3.81–3.65(m, 2H), 3.25(s, 1H), 2.49(s, 5H), 2.40–2.17(m, 4H), 2. 04–1.96 (m, 1H), 1.54 (dd, J=13.1, 6.8Hz, 5H), 1.37–1.16 (m, 12H), 1.04 (d, J=5.2Hz, 9H). 13 C NMR (101MHz, Methanol-d4) δ173.69, 172.00, 155.40, 151.97, 148.07, 146. 96, 144.23, 131.97, 130.08, 126.26, 122.09, 116.32, 102.48, 81.99, 79.99 ,74.70,70.67,69.55,66.58,61.92,59.04,56.54,48.76,48.28,36.78,34 .73, 33.12, 29.36, 29.07, 28.86, 28.66, 26.93, 25.99, 24.57, 22.57, 15.40.
[0217] (1) Compound numbered R-14 in Table 1
[0218] The target compound was prepared by referring to the method in Example 14. The product was a white solid with a yield of 55%.
[0219] 1 H NMR (400MHz, Chloroform-d) δ7.93 (s, 1H), 7.34 (t, J = 7.8Hz, 1H), 7.22 (d, J = 7.5Hz, 1H), 6.93 (dd, J = 4.6, 1.3Hz, 1H), 6.77 (d, J = 2.8Hz, 1H) , 6.68(d,J=4.6Hz,1H), 6.37(s,2H), 5.59–5.54(m,1H), 5.49(d,J=6.7Hz,1H), 5.29–5.05(m,2H), 4.92(dd,J=6.8,4.2Hz,1H), 4.60(dt,J=5 .9,4.2Hz,1H), 4.51–4.47(m,1H),4.45(dd,J=12.0,4.1Hz,1H), 4.31–4.27(m,1H), 4.26(d,J=6.3Hz,1H), 4.15(d,J=15.6Hz,1H), 3.19(d,J =7.0Hz,2H), 3.00–2.82(m,3H), 2.31–2.28(m,2H), 2.17–2.12(m,1H), 1.61(dt,J=15.7,7.6Hz,4H), 1.45–1.36(m,6H), 1.32–1.25(m,12H).
[0220] (11) Compound numbered R-15 in Table 1
[0221] The target compound was prepared by referring to the method in Example 15. The product was a white solid with a yield of 48%.
[0222] 1H NMR (400MHz, Methanol-d4) δ7.87(s,1H), 7.33(t,J=7.8Hz,1H), 7.08(dd,J=7.6,0.8Hz,1H), 6.91(q,J=4.6Hz,2H), 6.83(d ,J=8.0Hz,1H), 5.17(dd,J=13.3,5.2Hz,1H), 4.87(d,J=5.3Hz,1H), 4.66(s,1H), 4.46–4.30(m,5H), 4.18–4.15(m,1H), 3.2 1(t,J=7.1Hz,2H), 2.97–2.88(m,1H), 2.80(ddd,J=17.8,4.7,2.4Hz,1H), 2.54–2.44(m,1H), 2.31(td,J=7.4,5.0Hz,2H), 2 .19(ddt,J=10.5,5.4,2.7Hz,1H), 1.65(h,J=7.4,6.9Hz,2H), 1.60–1.53(m,2H), 1.41(d,J=7.7Hz,2H), 1.37–1.25(m,14H). 13 C NMR(101MHz,Methanol-d4)δ173.72,173.42,171.17,171.00,146.90,143.76,131.49,1 29.21,126.62,124.21,116.53,116.27,112.42,110.74,110.44,101.22,82.00,80.01,7 4.25,70.66,62.84,60.18,52.16,48.27,48.05,47.84,47.63,47.42,47.20,46.99,43.05,33.53,31.00,29.22,29.13,29.07,28.87,28.78,28.65,26.81,24.55,22.84,13.09.
[0223] (12) Compound numbered R-16 in Table 1
[0224] The target compound was prepared by referring to the method in Example 14. The product was a white solid with a yield of 33%.
[0225] 1H NMR (400MHz, Methanol-d4) δ7.88(s,1H), 7.33–7.15(m,2H), 6.94–6.83(m,4H), 4.88(d,J=5.2Hz,1H), 4.46–4.38(m,2H), 4.33(dd,J=11.4,4.8Hz,1H), 4.16(t,J=5.7Hz,1H), 3.93(h,J=6.5Hz,2H), 2.30(dt,J=7.4,3.6Hz,2H), 1 .78–1.69(m,2H), 1.59–1.54(m,2H), 1.48–1.39(m,2H), 1.36–1.19(m,14H).
[0226] (13) Compound numbered R-17 in Table 1
[0227] The target compound was prepared by referring to the method of Example 9. The product was a white solid with a yield of 39%.
[0228] 1 HNMR (400MHz, Methanol-d4) δ7.88 (s, 1H), 7.34–7.29 (m, 2H), 7.26 (d, J=7.6Hz, 1H), 7.19–7.10 (m, 3H), 7.07 (d, J=7.5Hz, 1 H), 6.94–6.87 (m, 2H), 6.80 (d, J=7.9Hz, 1H), 5.46–5.40 (m, 1H), 5.15 (q, J=5.9Hz, 2H), 4.56 (d, J=3.9Hz, 1H), 4.48–4.23 (m, 6H), 4.06–3.97(m, 1H), 3.97–3.84(m, 3H), 3.30–3.16(m, 4H), 3.03–2.86(m, 2H), 2.83–2.75(m, 2H), 2.51–2.35(m, 3H), 2.18 –1.97 (m, 3H), 1.66–1.56 (m, 4H), 1.47–1.43 (m, 2H), 1.38–1.32 (m, 16H), 1.28–1.24 (d, J=7.1Hz, 3H), 0.87 (t, J=7.4Hz, 6H). 13C NMR (101MHz, Methanol-d4) δ176.46, 174.51, 172.07, 171.64, 155.86, 152.35, 147.03, 143.78, 131.5 3, 129.76, 129.23, 127.41, 125.28, 124.15, 123.10, 119.98, 119.90, 116.85, 112.94, 111.52, 110.48 , 101.62, 81.72, 79.86, 78.93, 74.27, 72.95, 72.55, 66.75, 65.08, 53.86, 52.15, 50.68, 45.98, 44.86, 43.06, 40.71, 39.36, 32.73, 31.01, 29.07, 28.95, 28.79, 27.31, 25.23, 22.79, 20.17, 11.79, 10.87.
[0229] (14) Compound numbered R-18 in Table 1
[0230] The target compound was prepared by referring to the method in Example 11. The product was a white solid with a yield of 39%.
[0231] 1 HNMR (400MHz, Methanol-d4) δ8.88 (s, 1H), 7.87 (d, J=10.9Hz, 1H), 7.44 (d, J=2.6Hz, 4H), 6.92 (dd, J=12.5, 4.4Hz, 2H), 5 ... 4Hz, 1H), 4.19 (dd, J=6.2, 5.2Hz, 1H), 3.90–3.75 (m, 2H), 3.67 (dd, J=11.3, 3.7Hz, 1H), 2.49 (d, J=1.8Hz, 5H), 2.41 (dd, J =8.7, 2.7Hz, 1H), 2.36–2.20 (m, 4H), 2.02–1.94 (m, 1H), 1.61–1.49 (m, 7H), 1.30 (t, J = 7.6Hz, 2H), 1.03 (d, J = 4.5Hz, 9H). 13C NMR(101MHz,Methanol-d4)δ173.58,172.02,155.81,151.53,147.62,146.97, 144.24,131.97,130.08,129.09,126.26,124.24,123.99,116.81,116.55,111 .87,110.72,101.33,86.64,82.03,79.94,74.30,70.72,69.56,67.07,61.77,59.06,48.95,37.18,34.76,32.60,29.08,26.38,25.99,24.38,21.08,14.48.
[0232] (15) Compound numbered R-19 in Table 1
[0233] The target compound was prepared by referring to the method in Example 11. The product was a white solid with a yield of 25%.
[0234] 1 HNMR (400MHz, Methanol-d4) δ 8.87 (d, J = 1.4Hz, 1H), 7.88 (d, J = 7.8Hz, 1H), 7.42 (s, 4H), 6.96–6.93 (m, 1H), 6.91 (d, J = 4.6Hz, 1H ), 5.06–4.99(m, 2H), 4.70(q, J=3.6Hz, 1H), 4.50–4.40(m, 3H), 4.33(dd, J=7.5, 3.9Hz, 1H), 4.29(d, J=4.4Hz, 1H), 4.24–4.17(m , 1H), 4.10 (q, J=7.2Hz, 1H), 3.92–3.73 (m, 2H), 3.68 (dd, J=11.1, 3.5Hz, 1H), 3.31 (s, 1H), 2.48 (d, J=2.0Hz, 6H), 2.27 (dt, J=15 .5, 7.8Hz, 3H), 2.21–2.13 (m, 1H), 1.99 (dt, J=13.5, 4.4Hz, 1H), 1.52 (t, J=6.7Hz, 7H), 1.35–1.26 (m, 6H), 1.04 (d, J=3.1Hz, 9H). 13C NMR(101MHz,Methanol-d4)δ173.70,172.00,155.80,151.54,147.61,147.01,144.19 ,131.96,130.08,129.09,126.30,124.20,123.94,116.84,116.57,111.93,110.76,1 01.39,86.73,82.18,79.85,74.34,70.74,69.57,67.10,62.77,60.23,59.10,56.59,48.63,37.22,34.76,33.54,29.30,28.75,26.72,26.05,24.50,21.13,14.58,13.17.
[0235] (16) Compound numbered R-20 in Table 1
[0236] The target compound was prepared by referring to the method in Example 11. The product was a white solid with a yield of 29%.
[0237] 1 HNMR (400MHz, DMSO-d6) δ9.00 (s, 1H), 8.42 (d, J = 7.6Hz, 1H), 7.94 (d, J = 1.8Hz, 3H), 7.45 (d, J = 8.3Hz, 2H), 7.38 (d, J = 8.3Hz, 2H), 6.9 7–6.76 (m, 2H), 4.93 (d, J=7.3Hz, 1H), 4.67 (dd, J=16.4, 4.9Hz, 1H), 4.53 (t, J=8.1Hz, 1H), 4.35–4.14 (m, 3H), 4.08–4.01 (m, 1H), 3.99 –3.93(m, 1H), 3.69–3.61(m, 1H), 3.60–3.48(m, 4H), 3.01(s, 1H), 2.47(s, 3H), 2.42–2.37(m, 1H), 2.28(dt, J=7.5, 4.5Hz, 2H), 2.19( s, 1H), 1.79 (ddd, J=14.9, 7.6, 3.3Hz, 1H), 1.49 (t, J=6.9Hz, 2H), 1.40 (dd, J=12.8, 6.9Hz, 5H), 1.24 (d, J=11.4Hz, 12H), 0.92 (s, 9H).
[0238] (17) Compound numbered R-21 in Table 1
[0239] The target compound was prepared by referring to the method in Example 11. The product was a white solid with a yield of 34%.
[0240] 1 HNMR (400MHz, Methanol-d4) δ7.88 (s, 1H), 7.33–7.15 (m, 2H), 6.94–6.83 (m, 4H), 4.88 (d, J=5.2Hz, 1H), 4.46–4.38 (m, 2H), 4.33 (dd, J=11.4, 4.8Hz, 1H) , 4.16 (t, J=5.7Hz, 1H), 3.93 (h, J=6.5Hz, 2H), 2.30 (dt, J=7.4, 3.6Hz, 2H), 1 .78–1.69(m, 2H), 1.59–1.54(m, 2H), 1.48–1.39(m, 2H), 1.36–1.19(m, 14H). 13 C NMR(101MHz,Methanol-d4)δ173.67,171.69,155.79,151.54,147.63,146.98,144.21,131.9 6,130.11,129.11,126.28,124.25,124.04,116.82,116.57,111.92,110.81,101.34,86.63, 82.06,79.97,74.35,70.77,69.54,66.63,63.55,60.22,59.23,56.77,48.78,48.76,37.38,36.51,34.80,33.59,29.09,28.98,26.64,25.89,25.83,25.78,24.57,21.16,14.60,13.19.
[0241] (18) Compound numbered R-24 in Table 1
[0242] The target compound was prepared by referring to the method in Example 11. The product was a white solid with a yield of 34%.
[0243] 1H NMR (400MHz, Methanol-d4) δ8.90 (s, 1H), 7.89 (s, 1H), 7.47–7.42 (m, 4H), 6.94–6.89 (m, 2H), 5.03 (t, J = 7.0Hz, 2H), 4 .86(s,1H), 4.69(dd,J=9.1,7.8Hz,1H), 4.50–4.29(m,5H), 4.17–4.13(m,1H), 3.79(d,J=11.2Hz,1H), 3.67(dd,J=11. 1,3.6Hz,1H), 3.41(d,J=3.8Hz,1H), 2.56(tt,J=9.2,4.2Hz,2H), 2.50(s,3H), 2.32(td,J=7.4,4.7Hz,2H), 2.27–2.1 7(m,2H), 1.99(ddd,J=13.4,9.1,4.4Hz,1H), 1.55(dd,J=11.5,7.5Hz,7H), 1.36–1.27(m,14H), 1.06(d,J=3.9Hz,9H).
[0244] (19) Compound numbered R-25 in Table 1
[0245] The target compound was prepared by referring to the method in Example 13. The product was a white solid with a yield of 34%.
[0246] 1H NMR (400MHz, Chloroform-d) δ 8.71 (s, 1H), 7.94 (s, 1H), 7.49 (dd, J = 9.4, 7.4Hz, 1H), 7.47–7.37 (m, 4H), 7.00 (d, J = 4.6Hz, 1H), 6.68 (d, J = 4.6Hz, 1H), 6.5 2–6.40(m,2H), 5.44(d,J=6.6Hz,1H), 5.31(s,1H), 5.28–5.23(m,1H), 5.14– 5.08(m,1H), 4.73–4.66(m,2H), 4.60(d,J=8.9Hz,1H), 4.51(s,1H), 4.08(d, J=11.3Hz,1H), 3.98(dd,J=12.5,1.9Hz,1H), 3.85(d,J=12.3Hz,1H), 3.64(d d,J=11.4,3.8Hz,1H), 3.56(dq,J=13.5,6.8Hz,2H), 2.53(s,3H), 2.44–2.34 (m,1H), 2.16(t,J=7.5Hz,2H), 1.80(s,3H), 1.61(dd,J=19.3,12.0Hz,4H), 1 .51(d,J=6.9Hz,3H), 1.40(s,3H), 1.27(dd,J=8.5,5.8Hz,12H), 1.05(s,9H).
[0247] (20) Compound numbered R-27 in Table 1
[0248] The target compound was prepared by referring to the method in Example 11. The product was a white solid with a yield of 45%.
[0249] 1H NMR (400MHz, Methanol-d4) δ8.91(s,1H), 8.18–8.07(m,1H), 7.86(s,1H), 7.50–7.40(m,4H), 7.01–6.93(m,2H), 5.05(s, 2H), 4.74–4.60(m,4H), 4.48(s,1H), 4.33–4.29(m,1H), 4.25(dd,J=5.5,4.3Hz,1H), 3.94–3.80(m,3H), 3.76(dd,J=12.4 ,3.8Hz,1H), 3.66–3.62(m,1H), 3.26(s,1H), 3.21(dd,J=7.2,1.8Hz,2H), 2.82(s,2H), 2.50(s,3H), 2.23(dt,J=19.7,7. 5Hz, 4H), 2.07–1.95 (m, 2H), 1.83–1.77 (m, 2H), 1.62 (s, 4H), 1.54 (d, J = 7.0Hz, 3H), 1.34 (d, J = 3.9Hz, 14H), 1.15 (s, 9H).
[0250] (21) Compound numbered R-30 in Table 1
[0251] The target compound was prepared by referring to the method in Example 10. The product was a white solid with a yield of 49%.
[0252] 1 H NMR (400MHz, DMSO-d6) δ9.00 (s, 1H), 8.47 (d, J = 7.6Hz, 1H), 8.04 (s, 1H), 7.94 (d, J = 5.3Hz, 1H), 7.48–7.35 (m, 4H), 6.97–6.88 ( m,2H), 6.51(d,J=6.3Hz,1H), 5.20(dd,J=5.7,3.7Hz,1H), 5.11(t,J=5.4Hz,2H), 5.01–4.96(m,1H), 4.92(t,J=7.2Hz,1H), 4.5 4(t,J=8.2Hz,1H), 4.32–4.22(m,2H), 3.67–3.53(m,3H), 3.50(d,J=4.2Hz,1H), 3.18(d,J=3.1Hz,1H), 2.47(s,3H), 2.39(t,J= 7.3Hz,2H), 2.07(t,J=10.7Hz,1H), 1.82–1.73(m,1H), 1.66–1.54(m,2H), 1.44–1.35(m,5H), 1.35–1.18(m,12H), 0.95(s,9H).
[0253] (22) Compound numbered R-31 in Table 1
[0254] The target compound was prepared by referring to the method in Example 10. The product was a white solid with a yield of 57%.
[0255] 1 H NMR (400MHz, DMSO-d6) δ 9.00 (s, 1H), 8.47 (s, 1H), 7.93 (s, 2H), 7.47–7.37 (m, 4H), 6.92 (d, J = 4.5Hz, 1H), 6.90 (s, 1H) ), 5.24(d,J=5.2Hz,1H), 4.96(s,1H), 4.66(s,1H), 4.55(t,J=8.3Hz,1H), 4.30(s,1H), 4.15(q,J=5.2Hz,1H), 4.08(q ,J=4.4Hz,2H), 3.97(q,J=5.3Hz,2H), 3.69–3.58(m,3H), 3.55–3.50(m,2H), 3.19(s,1H), 2.47(s,3H), 2.27(t,J=7.3 Hz,2H), 2.10–2.02(m,1H), 1.84–1.74(m,1H), 1.50–1.45(m,2H), 1.43–1.35(m,5H), 1.32–1.19(m,4H), 0.96(s,9H).
[0256] (23) Compound numbered R-32 in Table 1
[0257] The target compound was prepared by referring to the method in Example 10. The product was a white solid with a yield of 55%.
[0258] 1H NMR (400MHz, Methanol-d4) δ8.89 (s, 1H), 7.85 (d, J = 1.9Hz, 1H), 7.47–7.41 (m, 4H), 7.03–6.95 (m, 1H), 6 .96–6.90(m,1H), 5.40(dd,J=5.9,2.8Hz,1H), 5.20(dd,J=5.9,3.4Hz,1H), 5.07–5.00(m,1H), 4.67(t,J= 8.4Hz,2H), 4.50–4.40(m,2H), 3.92–3.61(m,5H), 3.37(s,1H), 3.32(s,2H), 2.56–2.45(m,7H), 2.35–2. 18(m,2H), 2.05–2.14(m,1H), 1.73(t,J=7.2Hz,2H), 1.58–1.47(m,5H), 1.40–1.26(m,14H), 1.04(s,9H).
[0259] (24) Compound numbered R-36 in Table 1
[0260] The target compound was prepared by referring to the method in Example 18. The product was a white solid with a yield of 55%.
[0261] 1 H NMR (400MHz, Methanol-d4) δ7.87 (d, J = 2.5Hz, 1H), 7.77–7.73 (m, 2H), 7.66–7.61 (m, 2H), 7.19–7.13 (m ,2H), 6.91–6.85(m,4H), 5.56(dd,J=11.7,4.6Hz,1H), 5.51(s,1H), 4.87(dd,J=5.3,2.2Hz,1H), 4.46– 4.29(m,4H), 4.16–4.13(m,1H), 3.93(t,J=6.4Hz,2H), 3.37(s,1H), 3.21(dd,J=18.2,4.5Hz,1H), 2.33 –2.28(m,2H), 1.73(t,J=7.4Hz,2H), 1.58–1.54(m,2H), 1.42(d,J=8.7Hz,2H), 1.31(d,J=3.7Hz,12H).
[0262] (25) Compound numbered R-37 in Table 1
[0263] The target compound was prepared by referring to the method in Example 11. The product was a white solid with a yield of 34%.
[0264] 1H NMR (400MHz, DMSO-d6) δ9.00 (s, 1H), 8.42 (d, J = 7.6Hz, 1H), 7.94 (d, J = 1.8Hz, 3H), 7.45 (d, J = 8.3Hz, 2H), 7.38 (d, J = 8.3Hz, 2H), 6.97 –6.76(m,2H), 4.93(d,J=7.3Hz,1H), 4.67(dd,J=16.4,4.9Hz,1H), 4.53(t,J=8.1Hz,1H), 4.35–4.14(m,3H), 4.08–4.01(m,1H), 3.99 –3.93(m,1H), 3.69–3.61(m,1H), 3.60–3.48(m,4H), 3.01(s,1H), 2.47(s,3H), 2.42–2.37(m,1H), 2.28(dt,J=7.5,4.5Hz,2H), 2.19( s,1H), 1.79(ddd,J=14.9,7.6,3.3Hz,1H), 1.49(t,J=6.9Hz,2H), 1.40(dd,J=12.8,6.9Hz,5H), 1.24(d,J=11.4Hz,12H), 0.92(s,9H).
[0265] The chemical structures of the target compounds of the present invention synthesized above are shown in Table 1. Other compounds in Table 1 can be prepared by the above methods.
[0266] [Example 20] PROTAC compound biological activity test of remdesivir or GS-441524
[0267] (1) In vitro anti-EV71 virus activity of PROTAC compounds of remdesivir or GS-441524:
[0268] RD cells were plated at 3 × 10 4 The cells were inoculated in a 96-well plate at a density of 10 cells and cultured at 37°C and 5% CO2 for 24 hours. The cells were infected with EV71 virus at a multiplicity of infection (MOI) of 1 and adsorbed for 1 hour. Subsequently, each column of RD cells was treated with 1 μL of different test compound starting concentrations and 10-fold gradient dilutions in each well. After 24h and 48h of infection, the growth status of cells in each well was observed under a microscope, and cells treated with different concentrations were compared with normal untreated cells, and the proportion of cell state changes or death was marked to measure the cytopathic effect (CPE).
[0269] (2) PROTAC compound cytotoxicity assay of remdesivir or GS-441524:
[0270] Prepare 100 μL of 1 × 10 5The cell suspension in each well was pre-cultured in an incubator at 37°C and 5% CO2 for 24 hours. 10 μL of the test compound at different concentrations was added to the culture plate, and the culture plate was incubated in an incubator for 24 hours. 10 μL of CCK solution was added to each well, and the culture plate was incubated in an incubator for 1-4 hours. The absorbance at 450 nm was measured using an ELISA reader. Cell viability was analyzed and images were generated using GraphPad Prism 8.0 software.
[0271] (3) PROTAC compound RdRp degradation activity of remdesivir or GS-441524:
[0272] RD cells were plated in 6-well plates. When the cells grew to a density of about 60%, the medium was replaced with serum-free medium. 2 μg / well of the plasmid expressing the RNA polymerase protein dependent on the EV71 virus RNA was transfected with PEi (polyethyleneimine) at a mass volume ratio of 1:2. After 10 hours, the medium containing the transfection reagent was removed and medium containing gradient concentrations of the drug to be tested was added. After culturing for 24 hours at 37°C and 5% CO2, the supernatant was discarded, the cells were collected, and the lysis solution RAPI containing 1% PMSF (phenylmethylsulfonyl chloride) and 10% cocktail was added for lysis, and the content of RdRp protein was detected by Western Blot.
[0273] The present invention used remdesivir and GS-441524 as controls, and tested the cytotoxicity, virus inhibition activity and protein degradation activity of the synthesized compounds, and all activity results were calculated in μM.
[0274] Table 2 In vitro anti-EV71 results of some compounds synthesized by the present invention
[0275]
[0276]
[0277] As can be seen from the table, most compounds have good inhibitory activity against EV71 virus. Compounds R13, R14, R20, R21, R24, and R25 are significantly better than the control drug parent molecule GS-441524, which is comparable to remdesivir. On the other hand, R13, R14, R20, R21, R24, and R25 can target the degradation of RdRp, a key enzyme required for EV71 replication, in vitro in a ubiquitin-dependent pathway, which also significantly improves the activity of such compounds compared to GS-441524, the active metabolite of remdesivir, achieving an effect comparable to remdesivir.
[0278] Since PROTACs can be used to overcome drug resistance, it is an attractive strategy to apply PROTAC technology to the antiviral field. Since RdRp enzymes are key enzymes required for the replication of most RNA viruses and have obvious homology in the catalytic center, PROTACs that can degrade RdRp enzymes required for viral replication are the most promising direction among antiviral PROTACs. PROTACs do not need to have high affinity for target proteins when inducing protein degradation. This type of compound based on remdesivir or GS-441524 will be expected to overcome the gradually emerging remdesivir-resistant strains. It is an active and very promising EV71 RdRp inhibitor that can be used to prepare anti-EV71 drugs.
[0279] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A PROTAC compound of remdesivir or GS-441524, Features: The structure of the PROTAC compound of remdesivir is shown in the general formula (I); the structure of the PROTAC compound of GS-441524 is shown in the general formula (II) or (III); (I) (II) (III) In the above general formula, Linker is selected from , , , , , , , , , , , , , , , , the left end of the above-mentioned Linker is connected to Remdesivir or GS-441524, and the right end is connected to E3 ligase; E3 ligase ligands are selected from , , , , , , , .
2. A PROTAC compound of redecivir or GS-441524 according to claim 1, Features: The PROTAC compounds of remdesivir or GS-441524 are divided into series I PROTAC compounds of remdesivir, series II PROTAC compounds of GS-441524, series III PROTAC compounds of GS-441524, series IV PROTAC compounds of GS-441524, and series V PROTAC compounds of GS-441524; The structure of the PROTAC compound of series I remdesivir is shown in the general formula (I), wherein the linker is selected from , , , , , , , , E3 ligase is ; The structure of the PROTAC compound of series II GS-441524 is shown in general formula (II), and the linker is selected from , , , E3 ligase is ; The structure of the PROTAC compound of series III GS-441524 is shown in the general formula (III), and the linker is selected from , , , , , , , , , , , E3 ligase is selected from , ; The structure of the PROTAC compound of series IV GS-441524 is shown in the general formula (III), and the linker is selected from , , , , , , E3ligase is selected from , , ; The structure of the PROTAC compound of series V GS-441524 is shown in the general formula (III), and the linker is selected from , , E3 ligase is selected from , , .
3. A PROTAC compound of redecivir or GS-441524 according to claim 1, Features: Selected from the following compounds: 2-ethylbutyl (( S )-(((2 R , 3 S , 4 R , 5 R )-5-cyano-3,4-dihydroxy-5-(4-((2 S , 4 R )-4-hydroxy-2-((( S )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)hexylamino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate; 2-Ethylbutyl (( S )-(((2 R , 3 S , 4 R , 5 R )-5-cyano-3,4-dihydroxy-5-(4-((2 S , 4 R )-4-hydroxy-2-((( S )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)heptylamino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate; 2-Ethylbutyl (( S )-(((2 R , 3 S , 4 R , 5 R )-5-cyano-3,4-dihydroxy-5-(4-((2 S , 4 R )-4-hydroxy-2-((( S )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)octanamide)pyrrolo[2,1-f][1,2,4]triazin-7-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate; 2-Ethylbutyl (( S )-(((2 R , 3 S , 4 R , 5 R )-5-cyano-3,4-dihydroxy-5-(4-((2 S , 4 R )-4-hydroxy-2-((( S )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)nonyl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate; 2-Ethylbutyl (( S )-(((2 R , 3 S , 4 R , 5 R )-5-cyano-3,4-dihydroxy-5-(4-((2 S , 4 R )-4-hydroxy-2-((( S )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)decanoyl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate; 2-Ethylbutyl (( S )-(((2 R , 3 S , 4 R , 5 R )-5-cyano-3,4-dihydroxy-5-(4-((2 S , 4 R )-4-hydroxy-2-((( S )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-2,2-dimethyl-17-oxo-7,10,13-trioxo-4,16-diazepine-20-amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate; 2-Ethylbutyl (( S )-(((2 R , 3 S , 4 R , 5 R )-5-cyano-3,4-dihydroxy-5-(4-((2 S , 4 R )-4-hydroxy-2-((( S )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-2,2-dimethyl-17-oxo-7,10,13-trioxo-4,16-diazetidine-22-amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate; 2-Ethylbutyl (( S )-(((2 R , 3 S , 4R , 5 R )-5-cyano-3,4-dihydroxy-5-(4-((2 S , 4 R )-4-hydroxy-2-((( S )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-2,2-dimethyl-17-oxo-7,10,13-trioxo-4,16-diazatetracarbon-24-amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate; (2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)-6-((2-(2,6-dioxopiperidin-3-yl)-1-isoindol-4-yl)amino)hexanoate; ((2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)8-((2-(2,6-dioxopiperidin-3-yl)-1-isoindol-4-yl)amino)octanoate; (2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)-10-((2-(2,6-dioxopiperidin-3-yl)-1-isoindol-4-yl)amino)nonanoate; (2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)-10-((2-(2,6-dioxopiperidin-3-yl)-1-isoindol-4-yl)amino)decanoate; (2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)-11-((2-(2,6-dioxopiperidin-3-yl)-1-isoindol-4-yl)amino)undecanoate; (2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl 11-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1-isoindolin-4-yl)amino)undecanoate; ((2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)-12-((2-(2,6-dioxopiperidin-3-yl)-1-isoindol-4-yl)amino)dodecanoic acid methyl ester; (2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)-10-(4-(2,6-dioxopiperidin-3-yl)phenoxy)decanoate; 2-Ethylbutyl (( S )-(((2 R , 3 S , 4 R , 5 R )-5-cyano-5-(4-(1-(10-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)decanoyl)piperidine-4-carboxamide)pyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate; ((2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl 6-((( S )-1-((2 S , 4 R )-4-hydroxy-2-((( S )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)hexanoate; ((2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl 8-((( S )-1-((2 S , 4 R )-4-hydroxy-2-((( R )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)octanoate; (2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl 10-((( S )-1-((2S,4R)-4-hydroxy-2-((( S )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)decanoate; (2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl 11-((( S )-1-((2 S , 4 R )-4-hydroxy-2-((( R )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)undecanoate; ((2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl 10-((( S )-1-((2 R , 4 R )-4-hydroxy-2-((( S )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)decanoate; ((2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl 11-((( S )-1-((2 R , 4 R )-4-hydroxy-2-((( S )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)decanoate; (2 S , 4 R )-1-(( S )-2-(10-(((2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)decanamine)-3,3-dimethylbutyryl)-4-hydroxy- N -(( S )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide; (2 S , 4 R )-1-(( S )-2-(11-(((2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)decanamine)-3,3-dimethylbutyryl)-4-hydroxy- N- (( S )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide; ((2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl 4-((8-(((S)-1-((2 S , 4 R )-4-hydroxy-2-(((R)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)butanoate; ((2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl 4-((10-((( S )-1-((2 S , 4 R )-4-hydroxy-2-((( R )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-10-oxodecyl)butanoate; (2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl 6-((10-((( S )-1-((2 S , 4 R )-4-hydroxy-2-((( R )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-10-oxodecyl)hexanoate; ((2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl ( S )-3-((2 R , 4 R )-4-hydroxy-2-((( R )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-2,2-dimethyl-17-oxo-7,10,13-trioxo-4,16-diazetidine-20-carboxylate; (2 S , 4 R )-1-(( S )-2-((6-((7-((2 R , 3 S , 4 R , 5 R )-2-cyano-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-6-oxohexyl)amino)-3,3-dimethylbutyryl)-4-hydroxy-N-(( S )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide; (2 S , 4 R )-1-(( S )-2-((6-((7-((2 R , 3 S , 4 R , 5 R )-2-cyano-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-8-oxooctyl)amino)-3,3-dimethylbutyryl)-4-hydroxy- N -(( S )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide; (2 S , 4 R )-1-(( S )-2-((6-((7-((2R,3S,4R,5R)-2-cyano-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-10-oxodecanyl)amino)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide; (2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)-6-(( S )-2,6-bis((tert-butyloxycarbonyl)amino)hexylamino)hexanoate; (2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl 11-((S)-2,6-bis((tert-butyloxycarbonyl)amino)hexanamide)undecanoate; (2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)-6-((9H-fluoren-9-yl)amino)hexanoate; (2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl 11-(4-(3-(4-bromophenyl)-1-(2-chloroacetyl)-4,5-dihydropyrazol-5-yl)phenoxy)undecanoate; (2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl 11-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1-isoindolin-4-yl)amino)undecanoate; (2 R , 3 S , 4 R , 5 R )-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl 12-((( S )-1-((2 S , 4 R )-4-hydroxy-2-((( S )-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)dodecanoate.
4. A pharmacologically or physiologically acceptable salt of a PROTAC compound of remdesivir or GS-441524 according to any one of claims 1 to 3.
5. Use of the PROTAC compound of remdesivir or GS-441524 according to any one of claims 1 to 3 or the salt according to claim 4 in the preparation of an anti-EV71 drug or an EV71 RNA-dependent RNA polymerase inhibitor.
6. A pharmaceutical composition for use against EV71 or an inhibitor of EV71 RNA-dependent RNA polymerase, Features: At least one of the PROTAC compounds of remdesivir or GS-441524 described in any one of claims 1 to 3, or a pharmacologically or physiologically acceptable salt thereof.
7. The anti-EV71 pharmaceutical composition or EV71 RNA-dependent RNA polymerase inhibitor according to claim 6, Features: It also contains a pharmaceutically acceptable carrier or excipient.
